Does timing matter when initiating elagolix in a natural menstrual cycle?

Rachel B Danis, Intira Sriprasert, Frank Z Stanczyk, Richard J Paulson, Sharon A Winer, Jacqueline R Ho, Rachel B Danis, Intira Sriprasert, Frank Z Stanczyk, Richard J Paulson, Sharon A Winer, Jacqueline R Ho

Abstract

Objective: To investigate the efficacy of elagolix when administered at different time points in a menstrual cycle.

Design: Clinical case series.

Setting: Academic reproductive endocrinology center.

Patients: Ovulatory women not desiring pregnancy.

Interventions: Six doses of elagolix 200 mg were administered over 4 days, starting at 3 different points in a menstrual cycle: early follicular; late follicular; and midluteal. Serum follicle-stimulating hormone (FSH), luteinizing hormone (LH), estradiol (E2), and progesterone (P) concentrations were measured at baseline, during elagolix administration, and 1 day after the last dose. Transvaginal ultrasounds were performed to monitor follicle sizes.

Main outcome measures: Serum FSH, LH, E2, and P.

Results: Twelve women, four per group, completed the study. Subjects were 23-42 years of age. Demographics and ovarian reserve parameters were similar among participants. Elagolix suppressed FSH, LH, E2, and P when administered in the early follicular and midluteal phases but had mixed results when administered in the late follicular phase. Two participants demonstrated suppression of all four hormones. One participant ovulated, indicated by an increase in P concentration and development of a corpus luteum. A second participant did not ovulate yet demonstrated an increase in E2 concentration with growth of a dominant follicle. There were no significant differences in median percent change of hormone concentrations across study groups.

Conclusions: The results of this study suggest that elagolix can suppress the hypothalamic-pituitary-ovarian axis when initiated at different points in a menstrual cycle. Optimal dosing and treatment window for consistent hormone suppression have yet to be determined.

Clinical registration number: NCT04060992.

Keywords: Elagolix; GnRH antagonist; gonadotropin-releasing hormone (GnRH); hormone suppression; ovulation.

© 2021 The Authors.

Figures

Figure 1
Figure 1
Concentrations of (A) follicle-stimulating hormone (FSH), (B) luteinizing hormone (LH), (C) estradiol (E2), and (D) progesterone (P) for all 12 participants over the 5-day study period. Participants in study groups A, B, and C were divided by color (blue, yellow, and red, respectively). The Y-axis marks the hormone concentration. The X-axis marks the days in a menstrual cycle.

References

    1. Andreyko J.L., Marshall L.A., Dumesic D.A., Jaffe R.B. Therapeutic uses of gonadotropin-releasing hormone analogs. Obstet Gynecol Surv. 1987;42:1–21.
    1. Matsuo H., Arimura A., Nair R.M., Schally A.V. Synthesis of the porcine LH- and FSH-releasing hormone by the solid-phase method. Biochem Biophys Res Commun. 1971;45:822–827.
    1. Kumar P., Sharma A. Gonadotropin-releasing hormone analogs: understanding advantages and limitations. J Hum Reprod Sci. 2014;7:170–174.
    1. Fluker M., Grifo J., Leader A., Levy M., Meldrum D., Muasher S.J. Efficacy and safety of ganirelix acetate versus leuprolide acetate in women undergoing controlled ovarian hyperstimulation. Fertil Steril. 2001;75:38–45.
    1. Garcia-Velasco J.A., Isaza V., Vidal C., Landazábal A., Remohí J., Simón C. Human ovarian steroid secretion in vivo: effects of GnRH agonist versus antagonist (cetrorelix) Hum Reprod. 2001;16:2533–2539.
    1. Fluker M.R., Marshall L.A., Monroe S.E., Jaffe R.B. Variable ovarian response to gonadotropin-releasing hormone antagonist-induced gonadotropin deprivation during different phases of the menstrual cycle. J Clin Endocrinol Metab. 1991;72:912–919.
    1. Taylor H.S., Giudice L.C., Lessey B.A., Abrao M.S., Kotarski J., Archer D.F. Treatment of endometriosis-associated pain with elagolix, an oral GnRH antagonist. N Engl J Med. 2017;377:28–40.
    1. Surrey E., Taylor H.S., Giudice L., Lessey B.A., Abrao M.S., Archer D.F. Long-term outcomes of elagolix in women with endometriosis: results from two extension studies. Obstet Gynecol. 2018;132:147–160.
    1. Carr B.R., Stewart E.A., Archer D.F., Al-Hendy A., Bradley L., Watts N.B. Elagolix alone or with add-back therapy in women with heavy menstrual bleeding and uterine leiomyomas: a randomized controlled trial. Obstet Gynecol. 2018;132:1252–1264.
    1. Schlaff W.D., Ackerman R.T., Al-Hendy A., Archer D.F., Barnhart K.T., Bradley L.D. Elagolix for heavy menstrual bleeding in women with uterine fibroids. N Engl J Med. 2020;382:328–340.
    1. Ezzati M., Carr B.R. Elagolix, a novel, orally bioavailable GnRH antagonist under investigation for the treatment of endometriosis-related pain. Womens Health (Lond) 2015;11:19–28.
    1. Elagolix (Orilissa)--an oral GnRH antagonist for endometriosis pain. Med Lett Drugs Ther. 2018;60:158–160.
    1. Ng J., Chwalisz K., Carter D.C., Klein C.E. Dose-dependent suppression of gonadotropins and ovarian hormones by elagolix in healthy premenopausal women. J Clin Endocrinol Metab. 2017;102:1683–1691.
    1. Struthers R.S., Nicholls A.J., Grundy J., Chen T., Jimenez R., Yen S.S. Suppression of gonadotropins and estradiol in premenopausal women by oral administration of the nonpeptide gonadotropin-releasing hormone antagonist elagolix. J Clin Endocrinol Metab. 2009;94:545–551.
    1. Archer D.F., Ng J., Chwalisz K., Chiu Y.L., Feinberg E.C., Miller C.E. Elagolix suppresses ovulation in a dose-dependent manner: results from a 3-month, randomized study in ovulatory women. J Clin Endocrinol Metab. 2020;105:821–832.
    1. Marshall L.A., Fluker M.R., Jaffe R.B., Monroe S.E. Inhibition of follicular development by a potent antagonistic analog of gonadotropin-releasing hormone (detirelix) J Clin Endocrinol Metab. 1991;72:927–933.
    1. Marshall J.C., Griffin M.L. The role of changing pulse frequency in the regulation of ovulation. Hum Reprod. 1993;8(Suppl 2):57–61.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren